New Feature: A New Era for News on Finviz

XOMA Royalty Corporation; LAVA Therapeutics N.V.

Contributing Author

Recent Articles by XOMA Royalty Corporation; LAVA Therapeutics N.V.

Oct-17	XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement XOMA GlobeNewswire
Aug-04	XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right XOMA +10.01% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information